{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:24:12Z","timestamp":1784543052663,"version":"3.55.0"},"reference-count":66,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2018,2,10]],"date-time":"2018-02-10T00:00:00Z","timestamp":1518220800000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The elimination of hepatitis C virus <jats:bold>(<\/jats:bold><jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>) has been made possible through the availability of new antiviral drugs which may now be administered to all patients with <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> infection, even those with decompensated cirrhosis. The goal of the World Health Organization (<jats:styled-content style=\"fixed-case\">WHO<\/jats:styled-content>) is to reduce the incidence of chronic hepatitis infection from the current 6\u201010 million to 0.9 million cases of chronic infections by 2030, and annual deaths from 1.4 million to fewer than 0.5 million. Achieving these targets will require full implementation of epidemiological knowledge of <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> infection, screening and testing practices and strategies to link <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> patients to care. This review will focus on the current state of knowledge in the epidemiology of <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> and what can be done to increase patient awareness and reduce the barriers to treatment. Furthermore, we will discuss the role of <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> clearance on the control of <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\u2010related outcomes.<\/jats:p>","DOI":"10.1111\/liv.13668","type":"journal-article","created":{"date-parts":[[2018,2,10]],"date-time":"2018-02-10T12:00:22Z","timestamp":1518264022000},"page":"40-46","source":"Crossref","is-referenced-by-count":41,"title":["Is global elimination of <scp>HCV<\/scp> realistic?"],"prefix":"10.1111","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0287-1059","authenticated-orcid":false,"given":"Vincenza","family":"Calvaruso","sequence":"first","affiliation":[{"name":"Sezione di Gastroenterologia &amp; Epatologia DIBIMIS Universit\u00e0 di Palermo  Palermo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0822-9673","authenticated-orcid":false,"given":"Salvatore","family":"Petta","sequence":"additional","affiliation":[{"name":"Sezione di Gastroenterologia &amp; Epatologia DIBIMIS Universit\u00e0 di Palermo  Palermo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Crax\u00ec","sequence":"additional","affiliation":[{"name":"Sezione di Gastroenterologia &amp; Epatologia DIBIMIS Universit\u00e0 di Palermo  Palermo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,2,10]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2575"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512612"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512610"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512614"},{"key":"e_1_2_12_6_1","article-title":"Efficacy of Glecaprevir\/Pibrentasvir for 8 or 12 Weeks in Patients with HCV Genotype 2, 4, 5, or 6 Infection Without Cirrhosis","author":"Asselah T","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30496-6"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00052-9"},{"key":"e_1_2_12_9_1","first-page":"427","article-title":"Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. Lancet","volume":"2","author":"Petta S","year":"2017","journal-title":"Gastroenterol Hepatol"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2017.03.027"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.08.004"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)31916-5"},{"key":"e_1_2_12_13_1","article-title":"Effectiveness of Elbasvir\/Grazoprevir in Patients With Chronic Hepatitis C and Chronic Kidney Disease: Results From the Veterans Affairs System","volume":"111","author":"Kramer JR","year":"2017","journal-title":"J Hepatol"},{"key":"e_1_2_12_14_1","volume-title":"Global health sector strategy on viral hepatitis, 2016\u20132021: towards ending viral hepatitis","author":"World Health Organization","year":"2016"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30181-9"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30045-6"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)30849-8"},{"key":"e_1_2_12_18_1","unstructured":"WHO GUIDELINES FOR THE SCREENING CARE AND TREATMENT OF PERSONS WITH CHRONIC HEPATITIS C INFECTION. UPDATED VERSION APRIL 2016 Available fromhttp:\/\/www.who.int\/hepatitis\/publications\/hepatitis-c-guidelines-2016\/"},{"key":"e_1_2_12_19_1","unstructured":"GUIDELINES ON HEPATITIS B AND C. TESTING VERSION FEBRUARY 2017 Available fromhttp:\/\/www.who.int\/hepatitis\/publications\/guidelines-hepatitis-c-b-testing\/"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2010.01415.x"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126920"},{"key":"e_1_2_12_22_1","unstructured":"PapatheodoridisGV et\u00a0al.Hepatitis C: The beginning of the end\u2010key elements for successful European and national strategies to eliminate HCV in Europe. Report from EU HCV Policy Summit February 17 2016."},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2007.01912.x"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-5-201309030-00672"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.09.001"},{"key":"e_1_2_12_26_1","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Recommendations for Testing, Managing, and Treating Hepatitis C","volume":"62","author":"AASLD\/IDSA HCV Guidance","year":"2015","journal-title":"Hepatology"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2014.05.014"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-157-9-201211060-00529"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13135"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121450"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30075-4"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13012"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis815"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S30111"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26246"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2015.05.002"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23802"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13327"},{"key":"e_1_2_12_39_1","article-title":"Retreatment with sofosbuvir plus grazoprevir\/elbasvir plus ribavirin of patients with hepatitis C virus genotype 1 or 4 who previously failed a NS5A or NS3\u2010containing regimen. ANRS HC34 REVENGE","author":"L\u00e9dinghen V","year":"2017","journal-title":"Clin Infect Dis"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613512"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29256"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.02.039"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.09.007"},{"key":"e_1_2_12_44_1","article-title":"Can we prevent and modify cardiometabolic disorders by controlling HCV infection?","author":"Petta S","year":"2017","journal-title":"Gut"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20073"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23528"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.11.018"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-5-201303050-00005"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.03.036"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27623"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2007.06.022"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308163"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22703"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.06.012"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.07.016"},{"key":"e_1_2_12_56_1","doi-asserted-by":"crossref","unstructured":"KimWR MannalitharaA LeeH et\u00a0al.Survival Benefit of Direct\u2010Acting Antiviral Therapy in Patients with Decompensated Cirrhosis. AASLD 2017 LB 27.","DOI":"10.1016\/S0168-8278(18)30387-8"},{"key":"e_1_2_12_57_1","unstructured":"BackusL BelperioP ShahoumianT et\u00a0al.Population Health Services Veterans Affairs Palo Alto Health Care System Palo Alto CA. Impact of Sustained Virologic Response with Direct\u2010Acting Antiviral Treatment on Mortality and Hepatocellular Carcinoma. AASLD 2017 oral presentation 78."},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28753"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29364"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.10.037"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0485"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.09.009"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29344"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13825"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21403"},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.11.009"},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1336"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.13668","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.13668","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T02:53:48Z","timestamp":1694487228000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.13668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":66,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1111\/liv.13668"],"URL":"https:\/\/doi.org\/10.1111\/liv.13668","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2]]}}}